Skip to content

Author

Zhi-Pei Sang

We have 4 of 145 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Mechanisms underlying the effects of Buyang Huanwu Decoction against sepsis-induced ARDS using network pharmacology and experimental validation.

ETHNOPHARMACOLOGICAL RELEVANCE Buyang Huanwu Decoction (BYHW), a classic formula from Yilin Gaicuo Qing Dynasty, is indicated for stroke in patients with qi deficiency and blood stasis in the Chinese Pharmacopoeia. In traditional Chinese medicine (TCM), the pathogenesis of acute respiratory distress syndrome (ARDS) is...

Wan-Ying Tan, Chun-Yi Wang, Xiu-Xiu Liu et al. · 0 citations
Review Open access Oct 2026

Therapeutic Potential of Marine Natural Products Against Alzheimer’s Disease: Molecular Mechanisms, Druggability Evaluation and Clinical Translation Barriers

Alzheimer’s disease (AD) is an irreversible neurodegenerative disorder with complex multifactorial pathological cascades, including amyloid-β (Aβ) aggregation, tau hyperphosphorylation, sustained neuroinflammation, oxidative stress, cholinergic dysfunction and gut–brain axis imbalance. Current marketed anti-AD drugs me...

Dao-Wei Huang, Rou-Jun Lu, Chen-Chen Sheng et al. · 0 citations
Open access Sep 2026

ProST: an image prompt-guided multimodal representation learning framework for spatial domain identification

ProST is designed to effectively exploit morphology-aware information from histological images while reducing the impact of irrelevant visual noise, thereby generating robust and spatially coherent embeddings and making ProST a powerful tool for resolving fine-grained tissue structures and revealing underlying biologic...

Chen Sun, Zheng-Xia Wang, Qing-Chen Zhang et al. · 0 citations
Review Aug 2026

Overcoming the blood-brain barrier for therapeutics targeting neurodegenerative diseases: a patent review (2020-present).

INTRODUCTION The blood-brain barrier (BBB) restricts drug entry into the CNS, with most therapeutics showing < 1% brain penetration, limiting efficacy in neurodegenerative diseases. AREAS COVERED Patents (2020-2026) were retrieved from SciFinder, Web of Science, PubMed, and Reaxys using combinations of 'blood-brain b...

Daowei Huang, Roujun Lu, Rui-Jing Tang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.